Perspectives from recent advances of Helicobacter pylori vaccines research

alexandrossfakianakis shared this article with you from Inoreader Perspectives from recent advances of Helicobacter pylori vaccines research via Helicobacter Abstract Background Helicobacter pylori (H. pylori) infection is the main factor leading to some gastric diseases. Currently, H. pylori infection is primarily treated with antibiotics. However, with the widespread application of antibiotics, H. pylori resistance to antibiotics has also gradually increased year by year. Vaccines may be an alternative solution to clear H. pylori. Aims By reviewing the recent progress on H. pylori vaccines, we expected it to lead to more research efforts to accelerate breakthroughs in this field. Materials & Methods We searched the research on H. pylori vaccine in recent years through PubMed®, and then classified and summarized these studies. Results The study of the pathogenic mechanism of H. pylori has led to the development of vaccines using some antigens, such as urease, catalase, and heat shock protein (Hsp). Based on these antigens, whole-cell, subunit, nucleic acid, vector, and H. pylori exosome vaccines have been tested. Discussion At present, researchers have developed many types of vaccines, such as whole cell vaccines, subunit vaccines, vector vaccines, etc. However, although some of these vaccines induced protective immunity in mouse models, only a few were able to move into human trials. We propose that mRNA vaccine may play an important role in preventing or treating H. pylori infection. The current study shows that we have developed various types of vaccines based on the virulence factors of H. pylori. However, only a few vaccines have entered human clinical trials. In order to improve the efficacy of vaccines, it is necessary to enhance T-cell immunity. Conclusion We should fully understand the pathogenic mechanism of H. pylori and find its core antigen as a vaccine target. View on Web

Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.